Publikationen in Zusammenarbeit mit Forschern von University of Virginia (24)

2021

  1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

  2. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

  3. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

2019

  1. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  2. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415

2017

  1. Primary care requests for anaemia chemistry tests in Spain: Potential iron, transferrin and folate over-requesting

    Journal of Clinical Pathology, Vol. 70, Núm. 9, pp. 760-765

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

  2. Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis

    Journal of Thoracic and Cardiovascular Surgery, Vol. 152, Núm. 4, pp. 1142-1153

2010

  1. Identifying predictors of central nervous system disease in solid organ transplant recipientswith cryptococcosis

    Transplantation, Vol. 89, Núm. 1, pp. 69-74

  2. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients

    Clinical Infectious Diseases, Vol. 51, Núm. 9, pp. 1062-1069

2009

  1. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis

    Clinical Infectious Diseases, Vol. 49, Núm. 11, pp. 1721-1728

  2. Pulmonary zygomycosis in solid organ transplant recipients in the current era

    American Journal of Transplantation, Vol. 9, Núm. 9, pp. 2166-2171

  3. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome

    Journal of Infectious Diseases, Vol. 200, Núm. 6, pp. 1002-1011

2008

  1. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 2, pp. 735-738

  2. Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings

    Transplantation, Vol. 86, Núm. 5, pp. 647-651

  3. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen

    Clinical Infectious Diseases, Vol. 46, Núm. 2

2007

  1. Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality

    Journal of Infectious Diseases, Vol. 195, Núm. 5, pp. 756-764

2006

  1. Invasive aspergillosis in the recipients of liver retransplantation

    Liver Transplantation, Vol. 12, Núm. 8, pp. 1205-1209

2005

  1. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome

    Transplantation, Vol. 80, Núm. 8, pp. 1131-1133